Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) shares traded down 10.5% during mid-day trading on Thursday after an insider sold shares in the company. The stock traded as low as $6.23 and last traded at $6.25. 673,082 shares were traded during trading, a decline of 17% from the average session volume of 815,184 shares. The stock had previously closed at $6.98.
Specifically, insider David M. Spencer sold 40,000 shares of Bellicum Pharmaceuticals stock in a transaction dated Wednesday, July 18th. The stock was sold at an average price of $7.63, for a total value of $305,200.00. Following the sale, the insider now owns 99,939 shares of the company’s stock, valued at approximately $762,534.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $7.04, for a total value of $70,400.00. Following the completion of the sale, the chief technology officer now directly owns 89,939 shares in the company, valued at approximately $633,170.56. The disclosure for this sale can be found here. Company insiders own 9.84% of the company’s stock.
Several analysts have issued reports on the company. ValuEngine downgraded Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 21st. BidaskClub raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Cantor Fitzgerald set a $18.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 9th. Finally, Citigroup dropped their price target on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $14.48.
The company has a quick ratio of 10.24, a current ratio of 10.24 and a debt-to-equity ratio of 0.32. The stock has a market cap of $313.41 million, a PE ratio of -2.20 and a beta of 0.54.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.05). The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.08 million. equities research analysts predict that Bellicum Pharmaceuticals Inc will post -2.37 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC increased its position in shares of Bellicum Pharmaceuticals by 52.8% in the first quarter. Commonwealth Equity Services LLC now owns 18,888 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 6,530 shares during the last quarter. Knott David M increased its position in shares of Bellicum Pharmaceuticals by 12.8% in the first quarter. Knott David M now owns 67,653 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 7,669 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Bellicum Pharmaceuticals by 161.4% in the second quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 10,466 shares during the last quarter. Swiss National Bank increased its position in shares of Bellicum Pharmaceuticals by 32.3% in the second quarter. Swiss National Bank now owns 58,600 shares of the biopharmaceutical company’s stock valued at $432,000 after acquiring an additional 14,300 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in Bellicum Pharmaceuticals by 21.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 128,524 shares of the biopharmaceutical company’s stock worth $844,000 after purchasing an additional 22,335 shares during the period. 59.31% of the stock is currently owned by institutional investors and hedge funds.
Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
See Also: Tariff
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.